Buy Rating Affirmed for Gain Therapeutics Amidst Promising Clinical Trials and Strong Financial Health
Buy Rating Affirmed for Gain Therapeutics Amid Positive Clinical and Financial Performance
Adherex Technologies Inc. (FENC) Lags Q1 Earnings Estimates
Will Gain Therapeutics, Inc. (GANX) Report Negative Q1 Earnings? What You Should Know
Buy Rating Affirmed for Gain Therapeutics on Promising GT-02287 Clinical Progress
Buy Rating Affirmed for Gain Therapeutics on Promising GT-02287 Clinical Progress
Gain Therapeutics Shares Rise 8% After Positive Results From Early Trial of Parkinson's Disease Therapy
Gain Therapeutics Shares Rise 8% After Positive Results From Early Trial of Parkinson's Disease Therapy
Oppenheimer Remains a Buy on Gain Therapeutics (GANX)
Oppenheimer Remains a Buy on Gain Therapeutics (GANX)
Here's Why Gain Therapeutics (GANX) Could be Great Choice for a Bottom Fisher
Down -25.88% in 4 Weeks, Here's Why You Should You Buy the Dip in Gain Therapeutics (GANX)
Alpine Immune Sciences (ALPN) Moves 10.4% Higher: Will This Strength Last?
Buy Rating Affirmed for Gain Therapeutics on Promising Parkinson’s Treatment and Solid Financial Outlook
Optimistic Buy Rating for Gain Therapeutics Backed by Strong Financials and Promising Parkinson’s Drug Candidate GT-02287
•
in mil. unless spec.•
in mil. unless spec.•
in mil. unless spec.•
in mil. unless spec.•
in mil. unless spec.•
in mil. unless spec.